JP2021155442A - Nant癌ワクチン - Google Patents
Nant癌ワクチン Download PDFInfo
- Publication number
- JP2021155442A JP2021155442A JP2021107797A JP2021107797A JP2021155442A JP 2021155442 A JP2021155442 A JP 2021155442A JP 2021107797 A JP2021107797 A JP 2021107797A JP 2021107797 A JP2021107797 A JP 2021107797A JP 2021155442 A JP2021155442 A JP 2021155442A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cells
- vaccine
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940022399 cancer vaccine Drugs 0.000 title description 12
- 238000009566 cancer vaccine Methods 0.000 title description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 415
- 238000000034 method Methods 0.000 claims abstract description 96
- 239000000203 mixture Substances 0.000 claims abstract description 85
- 230000004044 response Effects 0.000 claims abstract description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 60
- 230000001939 inductive effect Effects 0.000 claims abstract description 51
- 238000011269 treatment regimen Methods 0.000 claims abstract description 50
- 230000033289 adaptive immune response Effects 0.000 claims abstract description 37
- 230000015788 innate immune response Effects 0.000 claims abstract description 34
- 230000008030 elimination Effects 0.000 claims abstract description 8
- 238000003379 elimination reaction Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 156
- 229960005486 vaccine Drugs 0.000 claims description 110
- 229940079593 drug Drugs 0.000 claims description 91
- 239000003814 drug Substances 0.000 claims description 91
- 201000011510 cancer Diseases 0.000 claims description 89
- 210000000822 natural killer cell Anatomy 0.000 claims description 85
- 239000000427 antigen Substances 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 238000004458 analytical method Methods 0.000 claims description 63
- 102000003812 Interleukin-15 Human genes 0.000 claims description 56
- 108090000172 Interleukin-15 Proteins 0.000 claims description 56
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 54
- 229960004397 cyclophosphamide Drugs 0.000 claims description 53
- 229960001592 paclitaxel Drugs 0.000 claims description 53
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 52
- -1 voltezomib Chemical compound 0.000 claims description 50
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 49
- 230000001506 immunosuppresive effect Effects 0.000 claims description 46
- 102000004127 Cytokines Human genes 0.000 claims description 44
- 108090000695 Cytokines Proteins 0.000 claims description 44
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 40
- 229960000397 bevacizumab Drugs 0.000 claims description 37
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 36
- 206010062016 Immunosuppression Diseases 0.000 claims description 36
- 108010088751 Albumins Proteins 0.000 claims description 35
- 102000009027 Albumins Human genes 0.000 claims description 35
- 108010002350 Interleukin-2 Proteins 0.000 claims description 34
- 102000000588 Interleukin-2 Human genes 0.000 claims description 34
- 229960002949 fluorouracil Drugs 0.000 claims description 31
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 30
- 238000002512 chemotherapy Methods 0.000 claims description 30
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 30
- 229960004316 cisplatin Drugs 0.000 claims description 29
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 29
- 230000003308 immunostimulating effect Effects 0.000 claims description 29
- 230000002483 superagonistic effect Effects 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 26
- 229960004641 rituximab Drugs 0.000 claims description 26
- 229930012538 Paclitaxel Natural products 0.000 claims description 22
- 102100034256 Mucin-1 Human genes 0.000 claims description 21
- 229960004679 doxorubicin Drugs 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 19
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 18
- 210000004322 M2 macrophage Anatomy 0.000 claims description 18
- 229960001756 oxaliplatin Drugs 0.000 claims description 18
- 229960001212 bacterial vaccine Drugs 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 16
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 16
- 229960003668 docetaxel Drugs 0.000 claims description 16
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 16
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 15
- 229940120638 avastin Drugs 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 14
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 13
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 13
- 229960000977 trabectedin Drugs 0.000 claims description 13
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 12
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 12
- 229960002411 imatinib Drugs 0.000 claims description 12
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 12
- 102000013691 Interleukin-17 Human genes 0.000 claims description 11
- 108050003558 Interleukin-17 Proteins 0.000 claims description 11
- 102100030703 Interleukin-22 Human genes 0.000 claims description 10
- 108010002586 Interleukin-7 Proteins 0.000 claims description 10
- 102000000704 Interleukin-7 Human genes 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 10
- 108010074108 interleukin-21 Proteins 0.000 claims description 10
- 239000008177 pharmaceutical agent Substances 0.000 claims description 10
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 9
- 210000005008 immunosuppressive cell Anatomy 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 229960004964 temozolomide Drugs 0.000 claims description 9
- 238000011285 therapeutic regimen Methods 0.000 claims description 9
- 210000002798 bone marrow cell Anatomy 0.000 claims description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 8
- 229960005420 etoposide Drugs 0.000 claims description 8
- 238000003068 pathway analysis Methods 0.000 claims description 8
- 230000008728 vascular permeability Effects 0.000 claims description 8
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 8
- 229960002066 vinorelbine Drugs 0.000 claims description 8
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 7
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 7
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 7
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 7
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 7
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 7
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 7
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 7
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 7
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 7
- 229960001573 cabazitaxel Drugs 0.000 claims description 7
- 229960002448 dasatinib Drugs 0.000 claims description 7
- 229960001904 epirubicin Drugs 0.000 claims description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960002584 gefitinib Drugs 0.000 claims description 7
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 7
- 229940076783 lucentis Drugs 0.000 claims description 7
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 7
- 229960000639 pazopanib Drugs 0.000 claims description 7
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 7
- 229960002087 pertuzumab Drugs 0.000 claims description 7
- 229940092597 prolia Drugs 0.000 claims description 7
- 229960002633 ramucirumab Drugs 0.000 claims description 7
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 7
- 229960002930 sirolimus Drugs 0.000 claims description 7
- 229960003787 sorafenib Drugs 0.000 claims description 7
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 7
- 229960001278 teniposide Drugs 0.000 claims description 7
- 229940079023 tysabri Drugs 0.000 claims description 7
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 6
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 6
- 229960002707 bendamustine Drugs 0.000 claims description 6
- 229960002938 bexarotene Drugs 0.000 claims description 6
- 229940022353 herceptin Drugs 0.000 claims description 6
- 229960000908 idarubicin Drugs 0.000 claims description 6
- 230000001338 necrotic effect Effects 0.000 claims description 6
- 229960005079 pemetrexed Drugs 0.000 claims description 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 6
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 6
- 229960003452 romidepsin Drugs 0.000 claims description 6
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 6
- 108010091666 romidepsin Proteins 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- 229960004854 viral vaccine Drugs 0.000 claims description 6
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 5
- 230000000711 cancerogenic effect Effects 0.000 claims description 5
- 108010021466 Mutant Proteins Proteins 0.000 claims description 4
- 102000008300 Mutant Proteins Human genes 0.000 claims description 4
- 231100000315 carcinogenic Toxicity 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 65
- 230000008629 immune suppression Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 195
- 238000012423 maintenance Methods 0.000 description 90
- 210000004369 blood Anatomy 0.000 description 82
- 239000008280 blood Substances 0.000 description 82
- 230000006698 induction Effects 0.000 description 59
- 230000014509 gene expression Effects 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 52
- 230000037449 immunogenic cell death Effects 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 49
- 238000007920 subcutaneous administration Methods 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 229950002916 avelumab Drugs 0.000 description 41
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 40
- 238000002347 injection Methods 0.000 description 40
- 239000007924 injection Substances 0.000 description 40
- 210000000987 immune system Anatomy 0.000 description 39
- 229940090044 injection Drugs 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 230000028993 immune response Effects 0.000 description 38
- 230000035772 mutation Effects 0.000 description 37
- 210000001744 T-lymphocyte Anatomy 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 35
- 108010057840 ALT-803 Proteins 0.000 description 34
- 201000010099 disease Diseases 0.000 description 34
- 238000001959 radiotherapy Methods 0.000 description 33
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 29
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 28
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 28
- 239000002775 capsule Substances 0.000 description 28
- 201000001441 melanoma Diseases 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 27
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 27
- 238000012216 screening Methods 0.000 description 27
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 27
- 230000027455 binding Effects 0.000 description 24
- 238000002591 computed tomography Methods 0.000 description 24
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 24
- 229960003301 nivolumab Drugs 0.000 description 22
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 21
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 21
- 235000008191 folinic acid Nutrition 0.000 description 21
- 239000011672 folinic acid Substances 0.000 description 21
- 229960001691 leucovorin Drugs 0.000 description 21
- 230000007774 longterm Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 20
- 230000007246 mechanism Effects 0.000 description 20
- 238000004393 prognosis Methods 0.000 description 20
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 19
- 229960004117 capecitabine Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102000016914 ras Proteins Human genes 0.000 description 19
- 108010014186 ras Proteins Proteins 0.000 description 19
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 241000701161 unidentified adenovirus Species 0.000 description 18
- 230000007717 exclusion Effects 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 13
- 230000030833 cell death Effects 0.000 description 13
- 238000002659 cell therapy Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 12
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 206010061818 Disease progression Diseases 0.000 description 11
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 230000005750 disease progression Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
- 201000002528 pancreatic cancer Diseases 0.000 description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 231100000617 superantigen Toxicity 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 208000000453 Skin Neoplasms Diseases 0.000 description 8
- 229940028652 abraxane Drugs 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 7
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000002600 positron emission tomography Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 201000000849 skin cancer Diseases 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000011272 standard treatment Methods 0.000 description 7
- 230000004797 therapeutic response Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 6
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 6
- 108010055044 Tetanus Toxin Proteins 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000005975 antitumor immune response Effects 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 235000008207 calcium folinate Nutrition 0.000 description 6
- 239000011687 calcium folinate Substances 0.000 description 6
- 229960005395 cetuximab Drugs 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 229940081995 fluorouracil injection Drugs 0.000 description 6
- 229960002258 fulvestrant Drugs 0.000 description 6
- 102000056003 human IL15 Human genes 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000011221 initial treatment Methods 0.000 description 6
- 229960002293 leucovorin calcium Drugs 0.000 description 6
- 238000007481 next generation sequencing Methods 0.000 description 6
- 230000002853 ongoing effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 229940118376 tetanus toxin Drugs 0.000 description 6
- 229940126580 vector vaccine Drugs 0.000 description 6
- 229940053867 xeloda Drugs 0.000 description 6
- 208000003950 B-cell lymphoma Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000006057 immunotolerant effect Effects 0.000 description 5
- 229940115970 lovaza Drugs 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000007479 molecular analysis Methods 0.000 description 5
- 230000004660 morphological change Effects 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 102200006520 rs121913240 Human genes 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 230000009946 DNA mutation Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- 108010043610 KIR Receptors Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 108091092259 cell-free RNA Proteins 0.000 description 4
- 229940105442 cisplatin injection Drugs 0.000 description 4
- 230000003138 coordinated effect Effects 0.000 description 4
- 229960003901 dacarbazine Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000037442 genomic alteration Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000005746 immune checkpoint blockade Effects 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102200006525 rs121913240 Human genes 0.000 description 4
- 102200006539 rs121913529 Human genes 0.000 description 4
- 102200006540 rs121913530 Human genes 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000402 unacceptable toxicity Toxicity 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 101150005585 E3 gene Proteins 0.000 description 3
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 102000002698 KIR Receptors Human genes 0.000 description 3
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 3
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 229940120655 eloxatin Drugs 0.000 description 3
- 210000002907 exocrine cell Anatomy 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000011528 liquid biopsy Methods 0.000 description 3
- 238000002624 low-dose chemotherapy Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000002956 necrotizing effect Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 102200055464 rs113488022 Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000011247 total mesorectal excision Methods 0.000 description 3
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 229960003862 vemurafenib Drugs 0.000 description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- 238000012070 whole genome sequencing analysis Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 2
- 101000945346 Homo sapiens Killer cell immunoglobulin-like receptor 2DS5 Proteins 0.000 description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 2
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 2
- 102100033626 Killer cell immunoglobulin-like receptor 2DS5 Human genes 0.000 description 2
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100021010 Nucleolin Human genes 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 101150013568 US16 gene Proteins 0.000 description 2
- 101150071882 US17 gene Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108010044762 nucleolin Proteins 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 102220311640 rs1382779104 Human genes 0.000 description 2
- 102200007373 rs17851045 Human genes 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SNKUSVNHTCUELQ-UHFFFAOYSA-N 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic aci Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=C(O)C=C1 SNKUSVNHTCUELQ-UHFFFAOYSA-N 0.000 description 1
- XQVKLMRIZCRVPO-UHFFFAOYSA-N 4-[(2-arsonophenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C12=CC=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=C1N=NC1=CC=CC=C1[As](O)(O)=O XQVKLMRIZCRVPO-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 108010077333 CAP1-6D Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101150045267 CEA gene Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- SDKQRNRRDYRQKY-UHFFFAOYSA-N Dioxacarb Chemical compound CNC(=O)OC1=CC=CC=C1C1OCCO1 SDKQRNRRDYRQKY-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 1
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 1
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 1
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 1
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 description 1
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 description 1
- 101001030591 Homo sapiens Mitochondrial ubiquitin ligase activator of NFKB 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 description 1
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 1
- 102100033629 Killer cell immunoglobulin-like receptor 2DL5A Human genes 0.000 description 1
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 1
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 1
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 1
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 description 1
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101150114927 MUC1 gene Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 1
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 102100038531 Mitochondrial ubiquitin ligase activator of NFKB 1 Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 201000011648 T-cell childhood lymphoblastic lymphoma Diseases 0.000 description 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 241000679125 Thoron Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000004905 short-term response Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000005851 tumor immunogenicity Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 150000003679 valine derivatives Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明の分野は、癌治療の組成物および方法であり、特にヒトの癌治療に関する。
最大耐量(MTD)での化学療法、細胞分裂を妨害する薬剤である、キナーゼ阻害剤を使用する標的治療、および高線量の放射線照射を伴う抗体療法を使用する従来の分子的情報のない治療レジメンは通常、免疫系を害し、よって免疫寛容原性細胞死をもたらし、これは次に癌の免疫監視の選択および回避を可能にし、かつ抵抗性の異質遺伝子性クローンの逃避を可能にし、結果として転移および不十分な長期間の予後をもたらす。よって、従来の治療のレジメンおよび現在の標準治療は、腫瘍の免疫編集の逃避相を気づかずに永続化させ免疫抑制のTME(腫瘍の微小環境)を支援する場合がある。
同様に、TME中への薬物コンジュゲートのエントリが、腫瘍の微小血管系の内皮のFcRn受容体を介して行われる場合、イムノグロブリンのFc部分を含む様々なコンジュゲートおよびキメラタンパク質が企図される。よって、特に企図されるコンジュゲートおよびキメラタンパク質は、免疫刺激性サイトカイン(たとえばIL−2、IL15など)、およびケモカイン(たとえばCXCL14 CD40Lなど)を含む。あるいは、TMEはまた、IL−2の透過性亢進ペプチド部分(PEP)を一般に使用して、腫瘍の微小血管系を破壊することにより、より非特異的な方法で標的化され得る。このような透過性賦活薬は、好ましくは、壊死性腫瘍細胞に結合する薬物および/またはサプレッサー細胞を阻害する薬物の投与と共に、または投与の前に、提供される。
以下の説明は、本発明の主題により患者の癌を治療するための例示的なプロトコルを提供する。これらのプロトコルは、特異的な化合物および組成物を単独でまたは組み合わせて列挙するが、代替的な化合物および組成物が、同じまたは同様の効果で提供され得ることを理解すべきである。さらに、用量およびスケジュールは、患者の年齢、癌のステージ、および総合的な健康状態に従い、変更され得る。
・オメガ−3−酸エチルエステル(経口[PO]により1日2回[BID][3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・フルベストラント(500mg IM)
・シクロホスファミド(50mg、経口(PO)、1日2回[BID])
・5−FU(24時間にわたり400mg/m2を連続IV注入)
・ロイコボリン(20mg/m2のIVボーラス投与)
・Nab−パクリタキセル(100mg IV)
・シスプラチン(40mg/m2 IV)
ETBX−011、ETBX−021、ETBX−051、ETBX−061(5×1011個のウイルス粒子[VP]/ワクチン/用量 皮下[SC])
・セツキシマブ(250mg IV)
・ニボルマブ(1時間にわたり3mg/kg IV)またはアベルマブ(1時間にわたり10mg/kg IV)
・SBRT(8Gyを超えない、正確な線量は放射線腫瘍医により決定される)
・ALT−803(10μg/kg SC aNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・オメガ−3−酸エチルエステル(経口[PO]により1日2回(BID)[3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・Nab−パクリタキセル(100mg IV)
・ニボルマブ(1時間にわたり3mg/kg IV)またはアベルマブ(1時間にわたり10mg/kg IV)
・セツキシマブ(250mg IV)
フルベストラント(500mg IM)
・カペシタビン(650mg/m2 PO BID)
・シクロホスファミド(50mg PO BID)
・ALT−803(10μg/kg SC)(aNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・ETBX−011、ETBX−021、ETBX−051、ETBX−061(5×1011個のVP/ワクチン/用量 皮下[SC])
・GI−4000、GI−6207、GI−6301(40YU/ワクチン/用量 SC)、AD5ベースのワクチンの投与後2時間。
・オメガ−3−酸エチルエステル(5×1gカプセル剤、経口[PO]による)
・ベバシズマブ(5mg/kg IV)
・シクロホスファミド(50mg、経口(PO)、1日2回[BID])
・5−FU(24時間にわたり連続的なIV注入として400mg/m2)
・ロイコボリン(20mg/m2のIVボーラス投与)
・Nab−パクリタキセル(100mg IV)
・シスプラチン(40mg/m2 IV)
・ETBX−051、ETBX−061(5×1011個のウイルス粒子[VP]/ワクチン/用量 皮下[SC])
・GI−6301(40酵母単位[YU]/用量 SC)、Ad5ベースのワクチンの投与後2時間
・アベルマブ(1時間にわたり10mg/kg、IV)
・SBRT(8Gyを超えない、正確な線量は放射線腫瘍医により決定される)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・オメガ−3−酸エチルエステル(5×1gのカプセル剤 PO)
・ベバシズマブ(5mg/kg IV)
・Nab−パクリタキセル(100mg IV)
・アベルマブ(1時間にわたり10mg/kg、IV)
・シクロホスファミド(50mg PO BID)
・カペシタビン(650mg/m2 PO BID)
・ALT−803(10μg/kg SC)(haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・ETBX−051、ETBX−061(5×1011個のVP/ワクチン/用量 SC)
・GI−6301(40YU/用量 SC)、Ad5ベースのワクチンの投与から2時間後
・オメガ−3−酸エチルエステル(経口[PO]により、1日2回[BID][3×1gのカプセル剤および2×1gのカプセル剤]
・ベバシズマブ(5mg/kg IV)
・シクロホスファミド(50mg PO BID)
・5−FU(24時間にわたり連続的なIV注入として400mg/m2)
・ロイコボリン(20mg/m2のIVボーラス投与)
・Nab−パクリタキセル(100mg IV)
・シスプラチン(40mg/m2 IV)
・ETBX−011、ETBX−051、ETBX−061(5×1011個のウイルス粒子[VP]/ワクチン/用量 皮下[SC])
・GI−6207、GI−6301(40酵母単位[YU]/ワクチン/用量 SC)、Ad5ベースのワクチンの投与後2時間
・アベルマブ(1時間にわたり10mg/kg、IV)またはニボルマブ(1時間にわたり3mg/kg、IV)
・SBRT(8Gyを超えない、正確な線量は放射線腫瘍医により決定される)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・オメガ−3−酸エチルエステル(PO BID[3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・Nab−パクリタキセル(100mg IV)
・アベルマブ(1時間にわたり10mg/kg、IV)またはニボルマブ(1時間にわたり3mg/kg、IV)
・シクロホスファミド(50mg PO BID)
・カペシタビン(650mg/m2 PO BID)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・ETBX−011、ETBX−051、ETBX−061(5×1011個のVP/ワクチン/用量 SC)
・GI−6301(40YU/用量 SC)、Ad5ベースのワクチンの投与後2時間
NHLは、2017年に72,240の新規の症例が診断されると推定される、米国で非常に蔓延している疾患であり、すべての癌のおよそ4%を占める。この疾患は、癌関連の死亡のうち9番目の死因であり、2017年には20,140名が死亡すると推定される。NHLは、B細胞リンパ腫またはT細胞リンパ腫として分類できる。米国のNHLの症例の約85%はB細胞リンパ腫である。B細胞リンパ腫は、びまん性大細胞型B細胞リンパ腫(DLBCL)、濾胞性リンパ腫、小リンパ球性リンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、Burkittリンパ腫、およびリンパ形質細胞性リンパ腫を含む、様々なサブタイプを含む。B細胞リンパ腫のうち、DLBCLは、最も一般的であり、通常は高悪性度の疾患である。濾胞性リンパ腫、小リンパ球性リンパ腫、辺縁帯リンパ腫、およびリンパ形質細胞性リンパ腫は、低悪性度の疾患である傾向がある。米国でのNHLの症例の15%未満が、T細胞リンパ腫である。B細胞リンパ腫と同様に、多くのT細胞リンパ腫のサブタイプが存在し、それは前駆Tリンパ芽球性リンパ腫および末梢性T細胞リンパ腫を含む。NHLを有する患者は通常、進行性のステージ(III/IV)の疾患を伴い、多くは、最初は無症候性である。
・オメガ−3−酸エチルエステル(経口[PO]により1日2回[BID][3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・シクロホスファミド(50mg PO BID)
・5−FU(24時間にわたり連続的なIV注入としての400mg/m2)
・ロイコボリン(20mg/m2のIVボーラス投与)
・Nab−パクリタキセル(100mg IV)
・オキサリプラチン(40mg/m2 IV)
・ETBX−061(5×1011個のウイルス粒子[VP]/用量 皮下[SC])
・アベルマブ(1時間にわたり10mg/kg、IV)
・SBRT(8Gyを超えない、正確な線量は放射線腫瘍医により決定される)
・リツキシマブ(375mg/m2 IV)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
維持相の持続期間は、誘導相の最後の治療の完了後最大1年である。維持相は、反復される2週間のサイクルを含む。ALT−803、Ad5ベースのワクチン(ETBX 061)、haNK細胞、アベルマブ、ベバシズマブ、カペシタビン、シクロホスファミド、nab−パクリタキセル、オメガ−3−酸エチルエステル、およびリツキシマブの治療レジメンを、2週間ごとに反復する。
・オメガ−3−酸エチルエステル(PO BID[3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・nab−パクリタキセル(100mg IV)
・アベルマブ(1時間にわたり10mg/kg、IV)
・シクロホスファミド(50mg PO BID)
・カペシタビン(650mg/m2 PO BID)
・リツキシマブ(375mg/m2 IV)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
ETBX−061(5×1011個のVP/用量 SC)
肺癌は、世界的に見て癌の主な原因であり、およそ5人に1人の、癌による死亡の原因であり、毎年合計約159万人が死亡している。全種類の肺癌の主なリスク因子は喫煙であり、肺癌の症例のおよそ85〜90%が、この原因によるものとされ得る。喫煙を中断する効果は、過去25年にわたり米国で肺癌の発症率の減少をもたらした。しかしながら、肺癌は、深刻な健康上の重荷を課し続けている。米国では、推定224,000の肺癌の新規の症例が、2016年に診断され、およそ158,000名の死亡が肺癌に起因すると考えられる。
・オメガ−3−酸エチルエステル(経口[PO]により1日2回(BID)[3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・フルベストラント(500mg IM)
・シクロホスファミド(50mg、経口(PO)、1日2回[BID])。
・5−FU(24時間にわたり400mg/m2を連続IV注入)
・ロイコボリン(20mg/m2のIVボーラス投与)
・Nab−パクリタキセル(100mg IV)
・シスプラチン(40mg/m2 IV)またはオキサリプラチン(40mg/m2 IV)
シスプラチンは、扁平上皮癌のサブタイプを有する対象に投与される。オキサリプラチンは、腺癌のサブタイプを有する対象に投与される。
・ETBX−011、ETBX−021、ETBX−051、ETBX−061(5×1011個のウイルス粒子[VP]/ワクチン/用量 皮下[SC])
・GI−4000、GI−6207、GI−6301(40酵母単位[YU]/ワクチン/用量 SC)、AD5ベースのワクチンの投与後2時間
プロスペクティブな腫瘍の分子プロファイリングは、上述のように、ETBX−021およびGI−4000を投与するかどうかを決定する。
・ニボルマブ(1時間にわたり3mg/kg IV)またはアベルマブ(1時間にわたり10mg/kg IV)
・SBRT(8Gyを超えない、正確な線量は放射線腫瘍医により決定される)
・ALT−803(10μg/kg SC haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・オメガ−3−酸エチルエステル(PO BID[3×1gのカプセル剤および2×1gのカプセル剤])
・ベバシズマブ(5mg/kg IV)
・Nab−パクリタキセル(100mg IV)
・ニボルマブ(1時間にわたり3mg/kg IV)またはアベルマブ(1時間にわたり10mg/kg IV)
・フルベストラント(500mg IM)
・カペシタビン(650mg/m2 PO BID)
・シクロホスファミド(50mg PO BID)
・ALT−803(10μg/kg SC)(haNK注入の30分前)
・haNK(2×109個の細胞/用量、IV)
・ETBX−011、ETBX−021、ETBX−051、ETBX−061(5×1011個のVP/ワクチン/用量 SC)
GI−4000、GI−6207、GI−6301(40YU/ワクチン/用量 SC)、Ad5ベースのワクチンの投与後2時間
膵臓癌は、米国での癌関連死の2番目の主な病因と推定されており、2017年には、この疾患による推定43,090名の死亡および推定53,670の新規の症例が予測される。これは、世界で12番目の最も一般的な癌であり、2012年には、およそ338,000の新規の症例が診断されている(全体の2%)。予後は不十分であり、結果として、膵臓癌は、世界で7番目の最も一般的な癌の死因であり、2012年には、膵臓癌により、330,000超の人々が死亡した(全体の4%)。
・シクロホスファミド(50mg 1日2回[BID])
・オキサリプラチン(40mg/m2 IV)
・Nab−パクリタキセル(125mg IV)
・ベバシズマブ(5mg/kg IV)
・5−フルオロウラシル(連続注入として24時間にわたり400mg/m2)
・ロイコボリン(20mg/m2のIVボーラス投与)
・SBRT(8Gy)
・ALT−803(10μg/kg 皮下[SC] aNK注入の30分前)
・aNK(2×109個の細胞/用量 IV)
・Ad5[E1−,E2b−]−CEA(5×1011個のVP/用量 SC)
・GI−4000(40酵母単位[YU]SC;必要とされるKRASの変異を表すゲノムのシークエンシングに応じて使用)
・アベルマブ(1時間にわたり10mg/kg、IV)
・シクロホスファミド(50mg BID)
・カペシタビン(650mg/m2 PO BID)
・Nab−パクリタキセル(125mg IV)
・ベバシズマブ(5mg/kg IV)
・アベルマブ(1時間にわたり10mg/kg、IV)
・ALT−803(10μg/kg SC)(aNK注入の30分前)
・aNK(2×109個の細胞/用量 IV)
・Ad5[E1−,E2b−]−CEA(5×1011個のVP/用量 SC)
・GI−4000(40YU SC)
軟部組織肉腫は、比較的珍しい癌である。それらは、毎年の新規の癌の全症例の1%未満を占める。これは、軟部組織中の細胞が、悪性腫瘍をより一般に引き起こす組織とは対照的に、絶え間なく細胞分裂していないためであり得る。
・シクロホスファミド50mg、1日2回(BID)
・ドキソルビシン20mg/m2 IV
・ベバシズマブ 5mg/kg IV
・トラベクテジン 0.5mg/kg IV
・nab−パクリタキセル 100mg IV
・SBRT 8Gy
・ALT−803 10μg/kg SC
・haNK 2×109個の細胞/用量、IV
・Ad5[E1−,E2b−]−MUC1 Ad5[E1−,E2b−]−ブラキュリ 5×1011個のVP/用量 SC
・GI−6301 Yeast ブラキュリ 40YU SC
・アベルマブ 10mg/kg 1時間ごと IV
・シクロホスファミド50mg、1日2回(BID)
・nab−パクリタキセル 100mg IV
・アベルマブ 10mg/kg IV
・ベバシズマブ 5mg/kg IV
・トラベクテジン 0.5mg/kg IV
・HaNK 2×109個の細胞/用量 IV
・ALT−803 10μg/kg SC
・Ad5[E1−,E2b−]−MUC1 Ad5[E1−,E2b−]−ブラキュリ 5×1011個のVP/用量 SC
・GI−6301 Yeast ブラキュリ 40YU SC
Claims (84)
- 腫瘍を治療するための協調した治療レジメンを提供する方法であって、
腫瘍の微小環境で免疫抑制を低減する少なくとも1つの第1の医薬組成物を投与することにより腫瘍の逃避相を戻すことと、
適応免疫応答および自然免疫応答の少なくとも1つを高める少なくとも1つの第2の医薬組成物を投与することにより腫瘍の排除相を誘導することと、
TH1応答に対する適応免疫応答を付勢する少なくとも1つの第3の医薬組成物を投与することにより腫瘍の平衡相を維持すること
を含む、方法。 - 前記第1の医薬組成物が、アルブミンに結合される薬物を含み、アルブミンが、任意選択でナノ粒子アルブミンである、請求項1に記載の方法。
- 前記アルブミンに結合される抗体またはそのフラグメントをさらに含む請求項2に記載の方法。
- 前記薬物が、ベンダムスチン、ボルテゾミブ、カバジタキセル、クロラムブシル、シスプラチン、シクロホスファミド、ダサチニブ、ドセタキセル、ドキソルビシン、エピルビシン、エルロチニブ、エトポシド、エベロリムス、ゲフィチニブ、イダルビシン、ヒドロキシウレア、イマチニブ、ラパチニブ、メルファラン、ミトキサントロン、ニロチニブ、オキサリプラチン(Oxiplatin)、パクリタキセル、パゾパニブ、ペメトレキセド、ラパマイシン、ロミデプシン、ソラフェニブ、ベムラフェニブ、スニチニブ、テニポシド、ビンブラスチン、ビノレルビン、およびビンクリスチンからなる群から選択される、請求項2または3に記載の方法。
- 前記抗体またはそのフラグメントが、レオプロ、カドサイラ、キャンパス、シムレクト、アバスチン、ベンリスタ、アドセトリス、シムジア、アービタックス(Rbitux)、プロリア、ゼヴァリン、タイサブリ、ガザイバ(Gazyva)、アーゼラ、ゾレア、ベクティビックス、パージェタ、サイラムザ、ルセンティス、リツキサン、ベキサロテン(bexar)、ヨンデリス、およびハーセプチンからなる群から選択される、請求項2〜4のいずれか1項に記載の方法。
- 前記抗体またはそのフラグメントが、壊死性細胞の成分に特異的に結合する、請求項2〜4のいずれか1項に記載の方法。
- 前記第1の医薬組成物が、T−reg細胞、骨髄由来免疫抑制細胞、およびM2マクロファージの少なくとも1つを阻害する薬物を含む、請求項1に記載の方法。
- 前記薬物が、シスプラチン、ゲムシタビン、5−フルオロウラシル、シクロホスファミド、ドキソルビシン、テモゾロミド、ドセタキセル、パクリタキセル、トラベクテジン、およびRP−182からなる群から選択される、請求項7に記載の方法。
- 前記第1の医薬組成物が、血管透過性賦活薬を含む、請求項1に記載の方法。
- 第1の血管透過性賦活薬が、少なくともIL2の一部を含む、請求項9に記載の方法。
- 前記第2の医薬組成物が、組み換え細菌ワクチン、組み換えウイルスワクチン、または組み換え酵母ワクチンを含む、請求項1〜10のいずれか1項に記載の方法。
- 前記組み換え細菌ワクチン、前記組み換えウイルスワクチン、または前記組み換え酵母ワクチンが、腫瘍関連抗原ならびに患者および腫瘍に特異的な新規エピトープの少なくとも1つを発現するように遺伝的に操作される、請求項11に記載の方法。
- 前記腫瘍関連抗原が、MUC1、CEA、HER2、ブラキュリ、および発癌性Ras変異タンパク質からなる群から選択される、請求項12に記載の方法。
- 前記第2の医薬組成物が、ナチュラルキラー細胞を含む、請求項1〜13のいずれか1項に記載の方法。
- 前記ナチュラルキラー細胞が、aNK細胞、haNK細胞、またはtaNK細胞である、請求項14に記載の方法。
- 前記第2の医薬組成物が、免疫刺激性サイトカインを含む、請求項1〜15のいずれか1項に記載の方法。
- 前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項16に記載の方法。
- 前記第3の医薬組成物が、チェックポイント阻害剤、免疫刺激性サイトカイン、組み換え細菌ワクチン、組み換えウイルスワクチン、および組み換え酵母ワクチンの少なくとも1つを含む、請求項1〜17のいずれか1項に記載の方法。
- 前記チェックポイント阻害剤が、PD−1阻害剤またはCTLA4阻害剤であり、前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項18に記載の方法。
- 前記腫瘍に低線量で放射線照射するステップをさらに含む請求項1〜19のいずれか1項に記載の方法。
- 前記抗体またはそのフラグメントが、レオプロ、カドサイラ、キャンパス、シムレクト、アバスチン、ベンリスタ、アドセトリス、シムジア、アービタックス(Rbitux)、プロリア、ゼヴァリン、タイサブリ、ガザイバ(Gazyva)、アーゼラ、ゾレア、ベクティビックス、パージェタ、サイラムザ、ルセンティス、リツキサン、ベキサロテン(bexar)、ヨンデリス、およびハーセプチンからなる群から選択される、請求項2または3に記載の方法。
- 前記抗体またはそのフラグメントが、壊死性細胞の成分に特異的に結合する、請求項21に記載の方法。
- 前記第1の医薬組成物が、T−reg細胞、骨髄由来免疫抑制細胞、およびM2マクロファージの少なくとも1つを阻害する薬物を含む、請求項1に記載の方法。
- 前記薬物が、シスプラチン、ゲムシタビン、5−フルオロウラシル、シクロホスファミド、ドキソルビシン、テモゾロミド、ドセタキセル、パクリタキセル、トラベクテジン、およびRP−182(米国特許第9492499号参照)からなる群から選択される、請求項23に記載の方法。
- 前記第1の医薬組成物が、血管透過性賦活薬を含む、請求項1に記載の方法。
- 前記第1の血管透過性賦活薬が、少なくともIL2の一部を含む、請求項25に記載の方法。
- 前記第2の医薬組成物が、組み換え細菌ワクチン、組み換えウイルスワクチン、または組み換え酵母ワクチンを含む、請求項1に記載の方法。
- 前記組み換え細菌ワクチン、前記組み換えウイルスワクチン、または前記組み換え酵母ワクチンが、腫瘍関連抗原ならびに患者および腫瘍に特異的な新規エピトープの少なくとも1つを発現するように遺伝的に操作される、請求項27に記載の方法。
- 前記腫瘍関連抗原が、MUC1、CEA、HER2、ブラキュリ、および発癌性Ras変異タンパク質からなる群から選択される、請求項28に記載の方法。
- 前記第2の医薬組成物が、ナチュラルキラー細胞を含む、請求項1に記載の方法。
- 前記ナチュラルキラー細胞が、aNK細胞、haNK細胞、またはtaNK細胞である、請求項30に記載の方法。
- 前記第2の医薬組成物が、免疫刺激性サイトカインを含む、請求項1に記載の方法。
- 前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項32に記載の方法。
- 前記第3の医薬組成物が、チェックポイント阻害剤、免疫刺激性サイトカイン、組み換え細菌ワクチン、組み換えウイルスワクチン、および組み換え酵母ワクチンの少なくとも1つを含む、請求項1に記載の方法。
- 前記チェックポイント阻害剤が、PD−1阻害剤またはCTLA4阻害剤であり、かつ前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項34に記載の方法。
- 前記腫瘍に低線量で放射線照射するステップをさらに含む請求項1に記載の方法。
- 腫瘍の免疫編集のプロセスを改変する方法であって、
腫瘍のオーミクス情報および前記腫瘍の経路解析を使用して化学療法の治療レジメンを決定することと、
前記化学療法の治療レジメンを低用量のメトロノミックなスケジュールで適用することと、
腫瘍の微小環境に薬物を選択的に送達する少なくとも1つの薬学的な薬剤を使用して第2の治療レジメンを適用することと、
前記オーミクス情報に基づく少なくとも1つのワクチン組成物を使用して第3の治療レジメンを適用することと、
チェックポイント阻害剤および免疫刺激性サイトカインの少なくとも1つを含む第4の治療レジメンを適用すること
を含む、方法。 - 前記オーミクス情報が、全ゲノム配列情報、エキソーム配列情報、トランスクリプトーム配列情報、およびプロテオミクス情報の少なくとも1つを含む、請求項37に記載の方法。
- 前記経路解析が、PARADIGM解析である、請求項37または38に記載の方法。
- 前記化学療法の治療レジメンが、前記腫瘍の解剖学的位置と無関係である、請求項37に記載の方法。
- 前記少なくとも1つの薬学的な薬剤が、アルブミンに結合される薬物を含み、アルブミンが、任意選択でナノ粒子アルブミンである、請求項37に記載の方法。
- 前記薬物が、ベンダムスチン、ボルテゾミブ、カバジタキセル、クロラムブシル、シスプラチン、シクロホスファミド、ダサチニブ、ドセタキセル、ドキソルビシン、エピルビシン、エルロチニブ、エトポシド、エベロリムス、ゲフィチニブ、イダルビシン、ヒドロキシウレア、イマチニブ、ラパチニブ、メルファラン、ミトキサントロン、ニロチニブ、オキサリプラチン(Oxiplatin)、パクリタキセル、パゾパニブ、ペメトレキセド、ラパマイシン、ロミデプシン、ソラフェニブ、ベムラフェニブ、スニチニブ、テニポシド、ビンブラスチン、ビノレルビン、およびビンクリスチンからなる群から選択される、請求項41に記載の方法。
- 前記薬剤が、前記アルブミンに結合される抗体またはそのフラグメントをさらに含む、請求項41に記載の方法。
- 前記抗体またはそのフラグメントが、レオプロ、カドサイラ、キャンパス、シムレクト、アバスチン、ベンリスタ、アドセトリス、シムジア、アービタックス(Rbitux)、プロリア、ゼヴァリン、タイサブリ、ガザイバ(Gazyva)、アーゼラ、ゾレア、ベクティビックス、パージェタ、サイラムザ、ルセンティス、リツキサン、ベキサロテン(bexar)、ヨンデリス、およびハーセプチンからなる群から選択される、請求項43に記載の方法。
- 前記少なくとも1つの薬学的な薬剤が、T−reg細胞、骨髄由来免疫抑制細胞、およびM2マクロファージの少なくとも1つを阻害する薬物を含む、請求項37に記載の方法。
- 前記薬物が、シスプラチン、ゲムシタビン、5−フルオロウラシル、シクロホスファミド、ドキソルビシン、テモゾロミド、ドセタキセル、パクリタキセル、トラベクテジン、およびRP−182からなる群から選択される、請求項45に記載の方法。
- 前記ワクチン組成物が、組み換え細菌ワクチン、組み換えウイルスワクチン、または組み換え酵母ワクチンを含む、請求項37に記載の方法。
- 前記ワクチン組成物が、少なくとも1つの患者および腫瘍に特異的な新規エピトープを発現するように遺伝的に操作される、請求項47に記載の方法。
- 前記チェックポイント阻害剤が、PD−1阻害剤またはCTLA4阻害剤であり、かつ前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項37に記載の方法。
- ナチュラルキラー細胞の投与および低線量での放射線の照射の少なくとも1つをさらに含む請求項37に記載の方法。
- 癌を治療するための協調した方法としての複数の医薬組成物の使用であって、
前記複数の医薬組成物の少なくとも1つの第1の医薬組成物が腫瘍の逃避相を戻すために腫瘍の微小環境中の免疫抑制を低減し、
前記複数の医薬組成物の少なくとも1つの第2の医薬組成物が腫瘍の排除相を誘導するために適応免疫応答および自然免疫応答の少なくとも1つを高め、
前記複数の医薬組成物の少なくとも1つの第3の医薬組成物が腫瘍の平衡相を維持するためにTH1応答に対する適応免疫応答を付勢する
ことを特徴とする、使用。 - 前記第1の医薬組成物が、アルブミンに結合される薬物を含み、アルブミンが、任意選択でナノ粒子アルブミンである、請求項51に記載の使用。
- 前記アルブミンに結合される抗体またはそのフラグメントをさらに含む請求項52に記載の使用。
- 前記薬物が、ベンダムスチン、ボルテゾミブ、カバジタキセル、クロラムブシル、シスプラチン、シクロホスファミド、ダサチニブ、ドセタキセル、ドキソルビシン、エピルビシン、エルロチニブ、エトポシド、エベロリムス、ゲフィチニブ、イダルビシン、ヒドロキシウレア、イマチニブ、ラパチニブ、メルファラン、ミトキサントロン、ニロチニブ、オキサリプラチン(Oxiplatin)、パクリタキセル、パゾパニブ、ペメトレキセド、ラパマイシン、ロミデプシン、ソラフェニブ、ベムラフェニブ、スニチニブ、テニポシド、ビンブラスチン、ビノレルビン、およびビンクリスチンからなる群から選択される、請求項52または53に記載の使用。
- 前記抗体またはそのフラグメントが、レオプロ、カドサイラ、キャンパス、シムレクト、アバスチン、ベンリスタ、アドセトリス、シムジア、アービタックス(Rbitux)、プロリア、ゼヴァリン、タイサブリ、ガザイバ(Gazyva)、アーゼラ、ゾレア、ベクティビックス、パージェタ、サイラムザ、ルセンティス、リツキサン、ベキサロテン(bexar)、ヨンデリス、およびハーセプチンからなる群から選択される、請求項52〜54のいずれか1項に記載の使用。
- 前記抗体またはそのフラグメントが、壊死性細胞の成分に特異的に結合する、請求項52〜54のいずれか1項に記載の使用。
- 前記第1の医薬組成物が、T−reg細胞、骨髄由来免疫抑制細胞、およびM2マクロファージの少なくとも1つを阻害する薬物を含む、請求51に記載の使用。
- 前記薬物が、シスプラチン、ゲムシタビン、5−フルオロウラシル、シクロホスファミド、ドキソルビシン、テモゾロミド、ドセタキセル、パクリタキセル、トラベクテジン、およびRP−182からなる群から選択される、請求項57に記載の使用。
- 前記第1の医薬組成物が、血管透過性賦活薬を含む、請求項51に記載の使用。
- 前記第1の血管透過性賦活薬が、少なくともIL2の一部を含む、請求項59に記載の使用。
- 前記第2の医薬組成物が、組み換え細菌ワクチン、組み換えウイルスワクチン、または組み換え酵母ワクチンを含む、請求項51〜60のいずれか1項に記載の使用。
- 前記組み換え細菌ワクチン、前記組み換えウイルスワクチン、または前記組み換え酵母ワクチンが、腫瘍関連抗原ならびに患者および腫瘍に特異的な新規エピトープの少なくとも1つを発現するように遺伝的に操作される、請求項61に記載の使用。
- 前記腫瘍関連抗原が、MUC1、CEA、HER2、ブラキュリ、および発癌性Ras変異タンパク質からなる群から選択される、請求項62に記載の使用。
- 前記第2の医薬組成物が、ナチュラルキラー細胞を含む、請求項51〜63のいずれか1項に記載の使用。
- 前記ナチュラルキラー細胞が、aNK細胞、haNK細胞、またはtaNK細胞である、請求項64に記載の使用。
- 前記第2の医薬組成物が、免疫刺激性サイトカインを含む、請求項51〜65のいずれか1項に記載の使用。
- 前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項66に記載の使用。
- 前記第3の医薬組成物が、チェックポイント阻害剤、免疫刺激性サイトカイン、組み換え細菌ワクチン、組み換えウイルスワクチン、および組み換え酵母ワクチンの少なくとも1つを含む、請求項51〜67のいずれか1項に記載の使用。
- 前記チェックポイント阻害剤が、PD−1阻害剤またはCTLA4阻害剤であり、かつ前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項68に記載の使用。
- 前記腫瘍に低線量で放射線照射するステップをさらに含む請求項51〜69のいずれか1項に記載の使用。
- 腫瘍の免疫編集プロセスを改変するための協調した治療レジメンとしての複数の化学療法の治療レジメンの使用であって、
化学療法の治療レジメンが低用量のメトロノミックなスケジュールで適用され、前記化学療法の治療レジメンが、腫瘍のオーミクス情報および腫瘍の経路解析を使用して決定される、
第2の治療レジメンが腫瘍の微小環境に薬物を選択的に送達する少なくとも1つの薬学的な薬剤を使用して適用され、
第3の治療レジメンがオーミクス情報に基づく少なくとも1つのワクチン組成物を使用して適用され、かつ
チェックポイント阻害剤および免疫刺激性サイトカインの少なくとも1つを含む第4の治療レジメンが適用される
ことを特徴とする、使用。 - 前記オーミクス情報が、全ゲノム配列情報、エキソーム配列情報、トランスクリプトーム配列情報、およびプロテオミクス情報の少なくとも1つを含む、請求項71に記載の使用。
- 前記経路解析が、PARADIGM解析である、請求項71または72に記載の使用。
- 前記化学療法の治療レジメンが、前記腫瘍の解剖学的位置と無関係である、請求項71に記載の使用。
- 前記少なくとも1つの薬学的な薬剤が、アルブミンに結合される薬物を含み、アルブミンが、任意選択でナノ粒子アルブミンである、請求項71に記載の使用。
- 前記薬物が、ベンダムスチン、ボルテゾミブ、カバジタキセル、クロラムブシル、シスプラチン、シクロホスファミド、ダサチニブ、ドセタキセル、ドキソルビシン、エピルビシン、エルロチニブ、エトポシド、エベロリムス、ゲフィチニブ、イダルビシン、ヒドロキシウレア、イマチニブ、ラパチニブ、メルファラン、ミトキサントロン、ニロチニブ、オキサリプラチン(Oxiplatin)、パクリタキセル、パゾパニブ、ペメトレキセド、ラパマイシン、ロミデプシン、ソラフェニブ、ベムラフェニブ、スニチニブ、テニポシド、ビンブラスチン、ビノレルビン、およびビンクリスチンからなる群から選択される、請求項75に記載の使用。
- 前記薬剤が、前記アルブミンに結合される抗体またはそのフラグメントをさらに含む、請求項75に記載の使用。
- 前記抗体またはそのフラグメントが、レオプロ、カドサイラ、キャンパス、シムレクト、アバスチン、ベンリスタ、アドセトリス、シムジア、アービタックス(Rbitux)、プロリア、ゼヴァリン、タイサブリ、ガザイバ(Gazyva)、アーゼラ、ゾレア、ベクティビックス、パージェタ、サイラムザ、ルセンティス、リツキサン、ベキサロテン(bexar)、ヨンデリス、およびハーセプチンからなる群から選択される、請求項77に記載の使用。
- 前記少なくとも1つの薬学的な薬剤が、T−reg細胞、骨髄由来免疫抑制細胞、およびM2マクロファージの少なくとも1つを阻害する薬物を含む、請求項71に記載の使用。
- 前記薬物が、シスプラチン、ゲムシタビン、5−フルオロウラシル、シクロホスファミド、ドキソルビシン、テモゾロミド、ドセタキセル、パクリタキセル、トラベクテジン、およびRP−182からなる群から選択される、請求項79に記載の使用。
- 前記ワクチン組成物が、組み換え細菌ワクチン、組み換えウイルスワクチン、または組み換え酵母ワクチンを含む、請求項71に記載の使用。
- 前記ワクチン組成物が、少なくとも1つの患者および腫瘍に特異的な新規エピトープを発現するように遺伝的に操作される、請求項81に記載の使用。
- 前記チェックポイント阻害剤が、PD−1阻害剤またはCTLA4阻害剤であり、かつ前記免疫刺激性サイトカインが、IL−2、IL−7、IL−15、IL−17、IL−21、およびIL−15スーパーアゴニストからなる群から選択される、請求項71に記載の使用。
- ナチュラルキラー細胞の投与および低線量での放射線の照射の少なくとも1つをさらに含む請求項71に記載の使用。
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357324P | 2016-06-30 | 2016-06-30 | |
US62/357,324 | 2016-06-30 | ||
US201662371665P | 2016-08-05 | 2016-08-05 | |
US62/371,665 | 2016-08-05 | ||
US201662393528P | 2016-09-12 | 2016-09-12 | |
US62/393,528 | 2016-09-12 | ||
US201662404753P | 2016-10-05 | 2016-10-05 | |
US62/404,753 | 2016-10-05 | ||
US201762463037P | 2017-02-24 | 2017-02-24 | |
US62/463,037 | 2017-02-24 | ||
US201762473207P | 2017-03-17 | 2017-03-17 | |
US62/473,207 | 2017-03-17 | ||
US201762474034P | 2017-03-20 | 2017-03-20 | |
US62/474,034 | 2017-03-20 | ||
JP2018569023A JP2019524692A (ja) | 2016-06-30 | 2017-06-30 | Nant癌ワクチン |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569023A Division JP2019524692A (ja) | 2016-06-30 | 2017-06-30 | Nant癌ワクチン |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021155442A true JP2021155442A (ja) | 2021-10-07 |
Family
ID=60787592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569023A Pending JP2019524692A (ja) | 2016-06-30 | 2017-06-30 | Nant癌ワクチン |
JP2021107797A Pending JP2021155442A (ja) | 2016-06-30 | 2021-06-29 | Nant癌ワクチン |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569023A Pending JP2019524692A (ja) | 2016-06-30 | 2017-06-30 | Nant癌ワクチン |
Country Status (12)
Country | Link |
---|---|
US (3) | US11207392B2 (ja) |
EP (2) | EP3478312A4 (ja) |
JP (2) | JP2019524692A (ja) |
KR (2) | KR20210010678A (ja) |
CN (1) | CN109789190A (ja) |
AU (2) | AU2017290803A1 (ja) |
CA (1) | CA3027911A1 (ja) |
IL (1) | IL264023A (ja) |
MX (1) | MX2018015796A (ja) |
SG (1) | SG11201811074RA (ja) |
TW (1) | TW201803598A (ja) |
WO (1) | WO2018005973A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017035392A1 (en) | 2015-08-25 | 2017-03-02 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
KR102317574B1 (ko) | 2015-11-18 | 2021-10-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
TW201803598A (zh) | 2016-06-30 | 2018-02-01 | 南特細胞公司 | Nant癌症疫苗 |
AU2017350957B2 (en) * | 2016-10-28 | 2020-10-29 | Nant Holdings Ip, Llc | Avatar dendritic cells: the neoantigen natural killer T-cell chemo immuno radiation composition inducing immunogenic cell death |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
AU2018263871A1 (en) * | 2017-05-03 | 2019-12-12 | Nantomics, Llc | Tumor vs. matched normal cfRNA |
WO2018208892A1 (en) * | 2017-05-10 | 2018-11-15 | Nantomics, Llc | Circulating rna for detection, prediction, and monitoring of cancer |
AU2018265534A1 (en) * | 2017-05-11 | 2019-10-31 | Nantkwest, Inc. | Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment |
CN111315401A (zh) * | 2017-06-16 | 2020-06-19 | 南特生物科学公司 | 细菌疫苗 |
EP3678672A4 (en) * | 2017-09-06 | 2021-06-02 | Nantcell, Inc. | ALDOXORUBICIN-BASED METHODS AND POLYTHERAPIES |
US10752682B2 (en) | 2017-11-01 | 2020-08-25 | Nantbio, Inc. | Anti-IL8 antibodies |
US11823773B2 (en) * | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
TWI787500B (zh) * | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
WO2020018425A1 (en) * | 2018-07-16 | 2020-01-23 | Nantcell, Inc. | Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201 |
AU2019343965A1 (en) * | 2018-09-20 | 2021-04-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Targeting moiety-drug grafted immune cell compositions and methods of use |
US11364265B1 (en) | 2019-03-15 | 2022-06-21 | Nantcell, Inc. | Recombinant erIL-15 NK cells |
WO2021071468A1 (en) * | 2019-10-07 | 2021-04-15 | Nantcell, Inc. | Neoepitope vaccine and immune stimulant combinations and methods |
WO2021096970A1 (en) * | 2019-11-12 | 2021-05-20 | Immunitybio, Inc. | Natural killer cell therapies |
WO2021108641A1 (en) | 2019-11-27 | 2021-06-03 | Immunitybio, Inc. | Methods of treating cancer |
CA3205637A1 (en) * | 2020-12-17 | 2022-06-23 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd20 targeted antibody |
US20230285528A1 (en) * | 2022-03-08 | 2023-09-14 | Immunitybio, Inc. | Intratumorally injected yeast vaccine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015097536A2 (en) * | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
WO2016004060A2 (en) * | 2014-06-30 | 2016-01-07 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
WO2016004876A1 (en) * | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
WO2016057554A1 (en) * | 2014-10-06 | 2016-04-14 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3054535A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN101291659A (zh) | 2005-08-31 | 2008-10-22 | 阿布拉科斯生物科学有限公司 | 包含水难溶性药剂和抗微生物剂的组合物 |
NZ592132A (en) | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
JP5548874B2 (ja) * | 2010-03-31 | 2014-07-16 | 富山県 | がん免疫抑制解除剤及びがん免疫治療用組成物 |
CA3007713C (en) | 2010-04-29 | 2020-05-26 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
WO2011149534A2 (en) | 2010-05-25 | 2011-12-01 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
GB2502750A (en) | 2011-03-22 | 2013-12-04 | Nant Holdings Ip Llc | Healthcare Management objects |
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2013192339A1 (en) | 2012-06-19 | 2013-12-27 | The Regents Of The University Of California | Biomarkers for the immunoediting-escape phase |
AU2013286622B2 (en) | 2012-07-06 | 2018-10-04 | Nant Holdings Ip, Llc | Healthcare analysis stream management |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CA2888125A1 (en) | 2012-10-09 | 2014-04-17 | Five3 Genomics, Llc | Systems and methods for learning and identification of regulatory interactions in biological pathways |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CA2920608C (en) | 2013-05-28 | 2018-07-24 | Five3 Genomics, Llc | Paradigm drug response networks |
EP3014505A4 (en) | 2013-06-28 | 2017-03-08 | Nantomics, LLC | Pathway analysis for identification of diagnostic tests |
US10114925B2 (en) | 2013-07-26 | 2018-10-30 | Nant Holdings Ip, Llc | Discovery routing systems and engines |
CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
CN104861067A (zh) * | 2014-01-10 | 2015-08-26 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015184439A1 (en) | 2014-05-30 | 2015-12-03 | Five3 Genomics, Llc | Systems and methods for comprehensive analysis of molecular profiles across multiple tumor and germline exomes |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
CN107106638A (zh) | 2014-10-14 | 2017-08-29 | 激流生物科学有限公司 | 具有抗炎特性的肽 |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
CN107548498A (zh) | 2015-01-20 | 2018-01-05 | 南托米克斯有限责任公司 | 用于反应预测高级别膀胱癌中的化疗的系统和方法 |
WO2016164833A1 (en) | 2015-04-08 | 2016-10-13 | Nantomics, Llc | Cancer neoepitopes |
WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
CN114272371A (zh) * | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
WO2017035392A1 (en) | 2015-08-25 | 2017-03-02 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
KR20240023699A (ko) | 2015-10-12 | 2024-02-22 | 난토믹스, 엘엘씨 | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 |
TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
WO2017139725A1 (en) | 2016-02-11 | 2017-08-17 | Nant Holdings Ip, Llc | Subcutaneous delivery of adenovirus with dual targeting |
US20210198689A1 (en) | 2016-03-18 | 2021-07-01 | Nant Holdings Ip, Llc | Multimodal Vector for Dendritic Cell Infection |
AU2017268822B2 (en) | 2016-05-27 | 2020-03-26 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
KR20190034160A (ko) | 2016-06-03 | 2019-04-01 | 이투빅스 코포레이션 | Her2/neu 가 관련되는 종양 백신화 및 면역요법을 위한 조성물 및 방법 |
TW201803598A (zh) | 2016-06-30 | 2018-02-01 | 南特細胞公司 | Nant癌症疫苗 |
-
2017
- 2017-06-30 TW TW106122120A patent/TW201803598A/zh unknown
- 2017-06-30 EP EP17821361.7A patent/EP3478312A4/en not_active Withdrawn
- 2017-06-30 US US16/312,246 patent/US11207392B2/en active Active
- 2017-06-30 WO PCT/US2017/040297 patent/WO2018005973A1/en active Search and Examination
- 2017-06-30 JP JP2018569023A patent/JP2019524692A/ja active Pending
- 2017-06-30 CA CA3027911A patent/CA3027911A1/en not_active Abandoned
- 2017-06-30 EP EP22182406.3A patent/EP4101447A1/en active Pending
- 2017-06-30 CN CN201780041456.4A patent/CN109789190A/zh active Pending
- 2017-06-30 MX MX2018015796A patent/MX2018015796A/es unknown
- 2017-06-30 KR KR1020217002163A patent/KR20210010678A/ko not_active IP Right Cessation
- 2017-06-30 KR KR1020197003046A patent/KR20190031492A/ko active Application Filing
- 2017-06-30 SG SG11201811074RA patent/SG11201811074RA/en unknown
- 2017-06-30 AU AU2017290803A patent/AU2017290803A1/en not_active Abandoned
-
2018
- 2018-12-30 IL IL264023A patent/IL264023A/en unknown
-
2020
- 2020-02-06 US US16/783,734 patent/US11071774B2/en active Active
- 2020-10-02 AU AU2020244589A patent/AU2020244589A1/en not_active Abandoned
-
2021
- 2021-06-29 JP JP2021107797A patent/JP2021155442A/ja active Pending
- 2021-08-02 US US17/391,694 patent/US11439697B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015097536A2 (en) * | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
WO2016004060A2 (en) * | 2014-06-30 | 2016-01-07 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
WO2016004876A1 (en) * | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
WO2016057554A1 (en) * | 2014-10-06 | 2016-04-14 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
MX2018015796A (es) | 2019-05-16 |
US11071774B2 (en) | 2021-07-27 |
IL264023A (en) | 2019-01-31 |
US20200171137A1 (en) | 2020-06-04 |
SG11201811074RA (en) | 2019-01-30 |
EP3478312A1 (en) | 2019-05-08 |
JP2019524692A (ja) | 2019-09-05 |
TW201803598A (zh) | 2018-02-01 |
EP3478312A4 (en) | 2020-07-29 |
US20210353730A1 (en) | 2021-11-18 |
US11207392B2 (en) | 2021-12-28 |
CN109789190A (zh) | 2019-05-21 |
KR20210010678A (ko) | 2021-01-27 |
US11439697B2 (en) | 2022-09-13 |
WO2018005973A1 (en) | 2018-01-04 |
US20190381156A1 (en) | 2019-12-19 |
CA3027911A1 (en) | 2018-01-04 |
EP4101447A1 (en) | 2022-12-14 |
AU2017290803A1 (en) | 2019-01-24 |
KR20190031492A (ko) | 2019-03-26 |
AU2020244589A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021155442A (ja) | Nant癌ワクチン | |
Kabacaoglu et al. | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options | |
KR20220149505A (ko) | 종양 세포 백신 | |
AU2018265534A1 (en) | Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment | |
KR20220024540A (ko) | 암 환자에서의 항종양 면역의 증진을 위한 환자 선택 | |
US20230000978A1 (en) | haNK Cetuximab Combinations And Methods | |
US11564980B2 (en) | Tumor treatment method with an individualized peptide vaccine | |
US20200352972A1 (en) | Aldoxorubicin combination treatments and methods | |
US20230034802A1 (en) | Nant Cancer Vaccine | |
US20240047009A1 (en) | Nant cancer vaccine strategies | |
Cornista et al. | Colorectal cancer immunotherapy: state of the art and future directions | |
Ma et al. | Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210726 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230208 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231020 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231113 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231124 |